Prior Authorization Form

DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS (FA-PA)

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS Caremark at **1-888-836-0730**. Please contact CVS Caremark at **1-855-240-0536** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Nesina (alogliptin).

Patie	nt Informatio	n					
Patie	nt Name:						
Patie	nt Phone:						
Patie	Patient ID:						
Patient Group No: Patient DOB:							
Physician Name: Physician Phone:							
Physician Address:							
City,	City, State, Zip:						
Drug	Name (spec	ify drug): Nesina (alogliptin)					
Quan	tity:	Frequency: Str	ength	:			
Route	of Adminis	tration: Expected Length of Therapy	: _				
Diagnosis: ICD Code:							
Comments:			_				
			_				
Pleas		appropriate answer for each applicable question. oducts are available at a lower cost. Can your patient be switched to a	Y		N		
		Formulary Alternatives: JANUVIA, TRADJENTA					
	[If yes, pro	ovide your patient with a new prescription for the preferred product.]					
2.		sted drug being used for an FDA-Approved indication OR an indication the compendia of current literature (examples: AHFS, Micromedex, current idelines)?	Y		N		
3.		escribed dose and quantity fall within the FDA approved labeling or within slines found in the compendia of current literature?	Y		N		
4.		ent tried and had an inadequate treatment response or intolerance to the nber of formulary alternatives below: Drug Name, Trial Year, Reason for	Y		N		
_	use or rec	nulary Alternatives should be prescribed first unless the patient is unable to eive treatment with the alternatives. Required Formulary Alternatives 2 in a 2 alternatives: JANUVIA, TRADJENTA					
	[If	yes, no further questions]					
5.	Does the par	tient have a contraindication to all the alternatives?	Y		N		

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate

and true, and that documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug Pas immediately and securely online – without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.